Blue­print Med­i­cines nabs 4th ap­proval in bid to­ward prof­itabil­i­ty

Blue­print Med­i­cines’ push to prof­itabil­i­ty con­tin­ues.

On Wednes­day, the Cam­bridge biotech an­nounced the FDA ap­proved its long­time lead drug, Ay­vak­it, for ad­vanced sys­temic mas­to­cy­to­sis, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER